Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR39 | O43194 | 7/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 4/20 | 0.35 |
| ▸ | DRD4 | P21917 | 4/20 | 0.35 |
| ▸ | DRD3 | P35462 | 4/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3722419 | 0.92 | GPR39 (0.48) | GPR39ACHEDRD2DRD4DRD3 | |
| SCHEMBL3720297 | 0.89 | GPR39 (0.38) | GPR39ACHEPDE2ADRD2DRD4 | |
| SCHEMBL3715855 | 0.87 | GPR39 (0.43) | GPR39ACHEPDE2ADRD2DRD4 | |
| SCHEMBL3717600 | 0.87 | GPR39 (0.41) | GPR39ACHEPDE2ADRD2DRD4 | |
| SCHEMBL3729038 | 0.86 | DRD2 (0.37) | PDE2ADRD2DRD4DRD3HCRTR1 | |
| SCHEMBL3718385 | 0.84 | DRD2 (0.38) | PDE2ADRD2DRD4DRD3HCRTR1 | |
| SCHEMBL3727903 | 0.84 | DRD2 (0.37) | PDE2ADRD2DRD4DRD3HCRTR1 | |
| SCHEMBL3718095 | 0.80 | GPR39 (0.39) | GPR39ACHEDRD2DRD4DRD3 | |
| SCHEMBL3721898 | 0.79 | GPR39 (0.44) | GPR39ACHEDRD2DRD4DRD3 | |
| SCHEMBL3719893 | 0.79 | GSK3B (0.43) | DRD2DRD4DRD3GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242742-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-8343966-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-01-01 | — | — | US | disclosed |
| EP-2242742-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
| WO-2009087212-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | GPR39 222/4885ACHE 1713/4885PDE2A 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.